Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Missouri: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 59 | 1,770 | 40% |
| 2020 | 41 | 1,572 | 43% |
| 2021 | 54 | 1,793 | 48% |
| 2022 | 55 | 1,847 | 51% |
| 2023 | 52 | 2,063 | 55% |
| 2024 | 58 | 2,381 | 57% |
| 2025 from claims | – | 2,680 2,460–2,836 | 58% |
| 2026 forecast | – | 2,901 2,553–3,348 | 58% |
| 2027 forecast | – | 3,135 2,680–3,735 | 59% |
| 2028 forecast | – | 3,386 2,825–4,146 | 60% |
| 2029 forecast | – | 3,657 2,987–4,586 | 60% |
| 2030 forecast | – | 3,948 3,163–5,060 | 61% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 39% of the cases CMS names in Missouri; 34 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 66% inpatient hospital, 32% hospital outpatient, 1% surgery center, 0% office. The share outside the hospital has moved −10 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~2,900 | ~2,000 | ~910 | ~33 |
| 2027 · ~3,100 | ~2,100 | ~960 | ~38 |
| 2028 · ~3,400 | ~2,300 | ~1,000 | ~42 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 68% (66% in 2025), hospital outpatient about 30% (32% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 125 | 4,051+13%/yr | +13%/yr | 2.6 | 15% | 6,990 in 2030+9.5%/yr |
| Ohio | 94 | 3,603+4.6%/yr | +4.6%/yr | 2.8 | 1% | 6,180 in 2030+9.4%/yr |
| Michigan | 82 | 3,065+2.7%/yr | +2.7%/yr | 3.1 | 17% | 4,880 in 2030+8.1%/yr |
| Indiana | 68 | 2,697+18%/yr | +18%/yr | 3.3 | 0% | 4,650 in 2030+9.5%/yr |
| Kansas | 56 | 2,663+15%/yr | +15%/yr | 6.0 | 5% | 4,850 in 2030+10%/yr |
| Wisconsin | 50 | 1,796+14%/yr | +14%/yr | 2.7 | 0% | 3,250 in 2030+10%/yr |
| Minnesota | 42 | 1,476+9.6%/yr | +9.6%/yr | 2.8 | 3% | 3,650 in 2030+16%/yr |
| Nebraska | 22 | 1,071+16%/yr | +16%/yr | 3.8 | 3% | 1,730 in 2030+8.3%/yr |
| Iowa | 21 | 859+11%/yr | +11%/yr | 1.8 | 5% | 1,760 in 2030+13%/yr |
| North Dakota | 15 | 600+12%/yr | +12%/yr | 5.5 | 0% | 1,190 in 2030+12%/yr |
| South Dakota | 11 | 481+17%/yr | +17%/yr | 3.4 | 0% | 890 in 2030+11%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 69 | 3,704−3.1%/yr | −3.1%/yr | 6.21.2× | 1% | 3,900 in 2030+0.9%/yr |
| EP ablation | 37 | 1,982+3.6%/yr | +3.6%/yr | 2.70.8× | 0% | 3,810 in 2030+11%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Missouri · Every state · Compare with Illinois
Boston Scientific leads with 74% of company spending on these surgeons in 2025, level with 2024.
In 2025, 4 companies reported engagement with Missouri’s surgeons worth $117K in consulting, speaking, meals and travel tied to these products, about $2,010 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.